Biochimica et biophysica acta. Reviews on cancer最新文献_第9页

Advancements in therapeutic peptides: Shaping the future of cancer treatment 治疗肽的进步：塑造癌症治疗的未来。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-10-14 DOI: 10.1016/j.bbcan.2024.189197

Xiaojie Chen , Zhiwei Zhao , Kyle Vaughn Laster , Kangdong Liu , Zigang Dong

{"title":"Advancements in therapeutic peptides: Shaping the future of cancer treatment","authors":"Xiaojie Chen , Zhiwei Zhao , Kyle Vaughn Laster , Kangdong Liu , Zigang Dong","doi":"10.1016/j.bbcan.2024.189197","DOIUrl":"10.1016/j.bbcan.2024.189197","url":null,"abstract":"<div><div>In the evolving landscape of cancer treatment, therapeutic peptides are assuming to play an increasingly vital role. Although the number of peptide drugs available for clinical cancer treatment is currently limited, extensive preclinical research is underway, presenting a promising trajectory for the future. The collaborative efforts of natural anti-cancer peptides (ACPs) and synthetic ACPs, propelled by advancements in molecular biology and peptide chemistry, are steering remarkable progress in this domain. We explores the intricate mechanisms underlying the anti-cancer effects of these peptides. The exploration of innovative strategies, including cancer immunotherapy and advanced drug delivery systems, is likely to contribute to the increasing presenceuse of peptide drugs in clinical cancer care. Furthermore, we delve into the potential implications and challenges associated with this anticipated shift, emphasizing the need for continued research and development to unlock the full therapeutic potential of peptide drugs in cancer treatment.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189197"},"PeriodicalIF":9.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies 人类乳头瘤病毒与宫颈癌的全面认识：病理生理学、筛查和疫苗接种策略。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-29 DOI: 10.1016/j.bbcan.2024.189192

Ying Liu, Hao Ai

引用次数: 0

Roles of miRNAs in regulating ovarian cancer stemness miRNA 在调节卵巢癌干性中的作用

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-29 DOI: 10.1016/j.bbcan.2024.189191

Zhi-Xiong Chong

{"title":"Roles of miRNAs in regulating ovarian cancer stemness","authors":"Zhi-Xiong Chong","doi":"10.1016/j.bbcan.2024.189191","DOIUrl":"10.1016/j.bbcan.2024.189191","url":null,"abstract":"<div><div>Ovarian cancer is one of the gynaecology malignancies with the highest mortality rate. Ovarian cancer stem cell (CSC) is a subpopulation of ovarian cancer cells with increased self-renewability, aggression, metastatic potentials, and resistance to conventional anti-cancer therapy. The emergence of ovarian CSC is a critical factor that promotes treatment resistance and frequent relapse among ovarian cancer patients, leading to poor clinical outcomes. MicroRNA (miRNA) is a short, non-protein-coding RNA that regulates ovarian CSC development. Although multiple original research articles have discussed the CSC-regulatory roles of different miRNAs in ovarian cancer, there is a deficiency of a review article that can summarize the findings from different research papers. To narrow the gap in the literature, this review aimed to provide an up-to-date summary of the CSC-regulatory roles of various miRNAs in modulating ovarian cancer cell stemness. This review will begin by giving an overview of ovarian CSC and the pathways responsible for driving its appearance. Next, the CSC-regulatory roles of miRNAs in controlling ovarian CSC development will be discussed. Overall, more than 60 miRNAs have been reported to play CSC-regulatory roles in the development and progression of ovarian cancer. By targeting various downstream targets, these miRNAs can control the signaling activities of PI3K/AKT, EGFR/ERK, WNT/ß-catenin, NF-kß, Notch, Hippo/YAP, EMT, and DNA repair pathways. Hence, these CSC-modulatory miRNAs have the potential to be used as prognostic biomarkers in predicting the clinical outcomes of ovarian cancer patients. Targeting CSC-promoting miRNAs or increasing the expressions of CSC-repressing miRNAs can help slow ovarian cancer progression. However, more in-depth functional and clinical trials must be carried out to evaluate the suitability, safety, sensitivity, and specificity of these CSC-regulating miRNAs as prognostic biomarkers or therapeutic targets.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189191"},"PeriodicalIF":9.7,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142359047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The tumor microenvironment's gambit: Exosomal pawns on the board of head and neck cancer 肿瘤微环境的赌局：头颈癌棋盘上的外泌体棋子

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-27 DOI: 10.1016/j.bbcan.2024.189189

Solmaz Mohamadi , Parisa Mehrasa , Bahareh Mehramuz , Sepehr Kobravi , Mohammad Taghizadieh , Arash Salmaninejad , Mobina Bayat , Javid Sadri Nahand

{"title":"The tumor microenvironment's gambit: Exosomal pawns on the board of head and neck cancer","authors":"Solmaz Mohamadi , Parisa Mehrasa , Bahareh Mehramuz , Sepehr Kobravi , Mohammad Taghizadieh , Arash Salmaninejad , Mobina Bayat , Javid Sadri Nahand","doi":"10.1016/j.bbcan.2024.189189","DOIUrl":"10.1016/j.bbcan.2024.189189","url":null,"abstract":"<div><div>The tumor microenvironment (TME) harbors a hidden universe of interactions that profoundly shape the behavior of head and neck cancers (HNCs). HNCs are not merely localized afflictions; they constitute a pressing global health crisis that impacts millions, frequently resulting in severe prognoses due to late-stage diagnosis and intrinsic resistance to conventional therapies. In this intricate interplay, cancer cells function as strategic players, adeptly manipulating their microenvironment to foster proliferation, evade immune detection, and withstand therapeutic interventions. Central to this dynamic play are exosomes, the enigmatic pawns of cellular communication, carrying vital messages across the board. This review elucidates the multifaceted roles of exosomes within the TME, highlighting their capacity to transmit critical signals that not only promote tumor progression but also modulate immune responses, ultimately playing a crucial role in the evolving narrative of HNC. Our insights aim to catalyze further research and exploration into exosome-targeted therapies, potentially transforming the landscape of HNC treatment and improving clinical outcomes in this formidable battle against cancer.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189189"},"PeriodicalIF":9.7,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The metabolic crosstalk of cancer-associated fibroblasts and tumor cells: Recent advances and future perspectives 癌症相关成纤维细胞和肿瘤细胞的代谢串扰：最新进展与未来展望

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-26 DOI: 10.1016/j.bbcan.2024.189190

Bing Xia , Liqing Qiu , Jing Yue , Jingxing Si , Hongfang Zhang

{"title":"The metabolic crosstalk of cancer-associated fibroblasts and tumor cells: Recent advances and future perspectives","authors":"Bing Xia , Liqing Qiu , Jing Yue , Jingxing Si , Hongfang Zhang","doi":"10.1016/j.bbcan.2024.189190","DOIUrl":"10.1016/j.bbcan.2024.189190","url":null,"abstract":"<div><div>Tumor cells grow in a microenvironment with a lack of nutrients and oxygen. Cancer-associated fibroblasts (CAFs) as one major component of tumor microenvironment have strong ability to survive under stressful conditions through metabolic remodelling. Furthermore, CAFs are educated by tumor cells and help them adapt to the hostile microenvironment through their metabolic communication. By inducing catabolism, CAFs release nutrients into the microenvironment which are taken up by tumor cells to satisfy their metabolic requirements. Furthermore, CAFs can recycle toxic metabolic wastes produced by cancer cells into energetic substances, allowing cancer cells to undergo biosynthesis. Their metabolic crosstalk also enhances CAFs' pro-tumor phenotype and reshape the microenvironment facilitating tumor cells' metastasis and immune escape. In this review, we have analyzed the effect and mechanisms of metabolic crosstalk between tumor cells and CAFs. We also analyzed the future perspectives in this area from the points of CAFs heterogeneity, spatial metabonomics and patient-derived tumor organoids (PDOs). These information may deepen the knowledge of tumor metabolism regulated by CAFs and provide novel insights into the development of metabolism-based anti-cancer strategies.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189190"},"PeriodicalIF":9.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination therapies with Wnt signaling inhibition: A better choice for prostate cancer treatment 抑制 Wnt 信号的联合疗法：前列腺癌治疗的更佳选择

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-25 DOI: 10.1016/j.bbcan.2024.189186

Yifan Hou , Zhenhua Zhao , Pan Li , Yujia Cao , Yi Zhang , Changsheng Guo , Xiaobo Nie , Junqing Hou

{"title":"Combination therapies with Wnt signaling inhibition: A better choice for prostate cancer treatment","authors":"Yifan Hou , Zhenhua Zhao , Pan Li , Yujia Cao , Yi Zhang , Changsheng Guo , Xiaobo Nie , Junqing Hou","doi":"10.1016/j.bbcan.2024.189186","DOIUrl":"10.1016/j.bbcan.2024.189186","url":null,"abstract":"<div><div>The intractability and high mortality rate of castration-resistant prostate cancer (CRPC) remain the most challenging problems in the field of prostate cancer (PCa). Emerging evidence has shown that the dysregulation of Wnt signaling pathways, which are highly conserved cascades that regulate embryonic development and maintain tissue homeostasis, is involved in various stages of PCa occurrence and progression. In this review, we systemically discuss the mechanisms by which the androgen receptor (AR) signaling pathway and Wnt signaling pathways participate in the occurrence of PCa and its progression to CRPC. Specifically, we elaborate on how Wnt signaling pathways induce the malignant transformation of prostate cells, promote the malignant progression of PCa and establish an immunosuppressive prostate tumor microenvironment through interaction with the AR pathway or in an AR-independent manner. We also discuss how Wnt signaling pathways enhances the stemness characteristics of prostate cancer stem cells (PCSCs) to induce the occurrence and metastasis of CPPC. Additionally, we discuss the latest progress in the use of different types of drugs that inhibit the Wnt signaling pathways in the treatment of PCa. We believe that the combination of Wnt signaling-based drugs with endocrine and other therapies is necessary and may enhance the clinical efficacy in the treatment of all types of PCa.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189186"},"PeriodicalIF":9.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence 针对胰腺导管腺癌的 DNA 损伤反应：临床前和临床证据综述。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-24 DOI: 10.1016/j.bbcan.2024.189185

Fatemeh Moosavi , Bahareh Hassani , Somayeh Nazari , Luciano Saso , Omidreza Firuzi

{"title":"Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence","authors":"Fatemeh Moosavi , Bahareh Hassani , Somayeh Nazari , Luciano Saso , Omidreza Firuzi","doi":"10.1016/j.bbcan.2024.189185","DOIUrl":"10.1016/j.bbcan.2024.189185","url":null,"abstract":"<div><div>Pancreatic ductal adenocarcinoma (PDAC) is associated with one of the most unfavorable prognoses across all malignancies. In this review, we investigate the role of inhibitors targeting crucial regulators of DNA damage response (DDR) pathways, either as single treatments or in combination with chemotherapeutic agents and targeted therapies in PDAC. The most prominent clinical benefit of PARP inhibitors' monotherapy is related to the principle of synthetic lethality in individuals harboring BRCA1/2 and other DDR gene mutations as predictive biomarkers. Moreover, induction of BRCAness with inhibitors of RTKs, including VEGFR and c-MET and their downstream signaling pathways, RAS/RAF/MEK/ERK and PI3K/AKT/mTOR in order to expand the application of PARP inhibitors in patients without DDR mutations, has also been addressed. Other DDR-targeting agents beyond PARP inhibitors, including inhibitors of ATM, ATR, CHEK1/2, and WEE1 have also demonstrated their potential in preclinical models of PDAC and may hold promise in future studies.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189185"},"PeriodicalIF":9.7,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation 细胞间粘附分子-1 (ICAM-1)：从分子功能到癌症研究中的临床应用

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-22 DOI: 10.1016/j.bbcan.2024.189187

Wen-Jing Qian , Jin-Shan Yan , Xiao-Yu Gang , Lu Xu , Sha Shi , Xin Li , Fang-Jian Na , Lu-tong Cai , He-Ming Li , Ming-Fang Zhao

{"title":"Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation","authors":"Wen-Jing Qian , Jin-Shan Yan , Xiao-Yu Gang , Lu Xu , Sha Shi , Xin Li , Fang-Jian Na , Lu-tong Cai , He-Ming Li , Ming-Fang Zhao","doi":"10.1016/j.bbcan.2024.189187","DOIUrl":"10.1016/j.bbcan.2024.189187","url":null,"abstract":"<div><div>Intercellular adhesion molecule-1 (ICAM-1) is a versatile molecule that plays a critical role in various physiological and pathological processes, particularly in tumor development where its impact is bidirectional. On the one hand, it augments the immune response by promoting immune cell migration, infiltration, and the formation of immunological synapses, thus facilitating potent antitumor effects. Simultaneously, it contributes to tumor immune evasion and influences metastasis by mediating transendothelial migration (TEM), epithelial-to-mesenchymal transition (EMT), and epigenetic modification of tumor cells. Despite its significant potential, the full clinical utility of ICAM-1 has yet to be fully realized. In this review, we thoroughly examine recent advancements in understanding the role of ICAM-1 in tumor development, its relevance in predicting therapeutic efficacy and prognosis, as well as the progress in clinical translational research on anti-ICAM-1-based therapies, encompassing including monoclonal antibodies, immunotherapy, antibody-drug conjugate (ADC), and conventional treatments. By shedding light on these innovative strategies, we aim to underscore ICAM-1's significance as a valuable and multifaceted target for cancer treatment, igniting enthusiasm for further research and facilitating translation into clinical applications.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189187"},"PeriodicalIF":9.7,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exosomal non-coding RNAs (ncRNAs) as potential biomarkers in tumor early diagnosis 外泌体非编码 RNA（ncRNA）作为肿瘤早期诊断的潜在生物标记物。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-21 DOI: 10.1016/j.bbcan.2024.189188

Jingyue Chang , Lingquan Zhang , Zeting Li , Chungen Qian , Juan Du

引用次数: 0

Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors 揭开 MGMT 的神秘面纱：对神经内分泌肿瘤的影响。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-09-18 DOI: 10.1016/j.bbcan.2024.189184

Jianyun Jiang , Junfeng Xu , Shunrong Ji , Xianjun Yu , Jie Chen

{"title":"Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors","authors":"Jianyun Jiang , Junfeng Xu , Shunrong Ji , Xianjun Yu , Jie Chen","doi":"10.1016/j.bbcan.2024.189184","DOIUrl":"10.1016/j.bbcan.2024.189184","url":null,"abstract":"<div><div>Neuroendocrine tumors (NETs) are a diverse group of tumors that arise from neuroendocrine cells and are commonly found in various organs. A considerable proportion of NET patients were diagnosed at an advanced or metastatic stage. Alkylating agents are the primary treatment for NET, and O<sup>6</sup>-methylguanine methyltransferase (<em>MGMT</em>) remains the first-line of defense against DNA damage caused by these agents. Clinical trials have indicated that <em>MGMT</em> promoter methylation or its low/lacked expression can predict a favorable outcome with Temozolomide in NETs. Its status could help select NET patients who can benefit from alkylating agents. Therefore, <em>MGMT</em> status serves as a biomarker to guide decisions on the efficacy of Temozolomide as a personalized treatment option. Additionally, delving into the regulatory mechanisms of <em>MGMT</em> status can lead to the development of <em>MGMT</em>-targeted therapies, benefiting individuals with high levels of <em>MGMT</em> expression. This review aims to explore the polymorphism of <em>MGMT</em> regulation and summarize its clinical implications in NETs, which would help establish the role of <em>MGMT</em> as a biomarker and its potential as a therapeutic target in NETs. Additionally, we explore the benefits of combining Temozolomide and immunotherapy in <em>MGMT</em> hypermethylated subgroups. Future studies can focus on optimizing Temozolomide administration to induce specific immunomodulatory changes.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189184"},"PeriodicalIF":9.7,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0